<table width="652px" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6. Established and Other Potentially Significant Drug Interactions with Ganciclovir</caption>
<colgroup>
<col></col>
<col></col>
<col></col>
</colgroup>
<thead>
<tr stylecode="First Last">
<th align="center" stylecode="Botrule Lrule Rrule Toprule" valign="top">Name of the Concomitant Drug</th>
<th align="center" stylecode="Botrule Lrule Rrule Toprule" valign="top">Change in the Concentration of Ganciclovir or Concomitant Drug</th>
<th align="center" stylecode="Botrule Lrule Rrule Toprule" valign="top">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Didanosine</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> ↑ Didanosine</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">
<paragraph>Patients should be closely monitored for didanosine toxicity.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Zidovudine</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> ↓ Ganciclovir<br/> ↑ Zidovudine                                                                                                                                                                                                     </td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Dose reduction or interruption may be needed because both zidovudine and ganciclovir have the potential to cause neutropenia and anemia. Monitor with frequent tests of white blood cell counts with differential and hemoglobin levels.<paragraph></paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Probenecid</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> ↑ Ganciclovir</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">GANCICLOVIR INJECTION dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.<paragraph></paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Imipenem-cilastatin</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Unknown</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">
<paragraph>Coadministration with imipenem-cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Cyclosporine or amphotericin B</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Unknown</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Monitor renal function when GANCICLOVIR INJECTION is co-administered with cyclosporine or amphotericin B because of potential increase in serum creatinine [see Warnings and Precautions (<linkhtml href="#Lc08003ad-1c7c-41b3-af6d-dbb8fa7622f5">5.2</linkhtml>)].</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Dapsone, pentamidine, flucytosine, vincristine, vinblastine, adriamycin, amphotericin B, trimethoprim/sulfamethoxazole combinations or other nucleoside analogues</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top"> Unknown</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Co-administration with GANCICLOVIR INJECTION should be considered only if the potential benefits are judged to outweigh the risks because of potential additive toxicity.</td>
</tr>
</tbody>
</table>